Avantor, Inc. · AVTR · FY2026 Q3 · Calendar Q4 2026
Avantor reports stronger growth and raises full-year guidance
The supplied analysis supports a constructive but conditional view: improving demand, execution under the Revival program, and digital productivity initiatives strengthen the operating trajectory, while margin durability and macro exposure remain important tests.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about AVTR FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the supplied Q3 assessment shows stronger organic growth across VWR and BMP, raised full-year guidance, continued deleveraging, and expanded AI and digital initiatives. Management also highlighted a new AI-driven Internal Sales Assistant and further manufacturing productivity.
Guidance delta
Management raised full-year organic revenue, EPS, and free-cash-flow guidance.
Key takeaways
- VWR and BMP returned to positive organic growth, supporting a stronger quarter.
- The Revival program is producing commercial and operational improvements.
- Free cash generation is supporting deleveraging alongside targeted investment.
- AI tools, e-commerce, and digital manufacturing remain key execution priorities.
Management priorities
- Continue the Revival program and operational improvements
- Expand AI tools, e-commerce, and digital manufacturing capabilities
- Improve supply-chain execution while reducing adjusted net leverage
Follow AVTR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationAvantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ICLR ICON Public Limited Company | FY2026 Q3 · Calendar Q4 2026 | — | +12.5% | ICON: bookings and margins improve as revenue dips |
| IQV IQVIA Holdings Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.5% | -0.7% | IQVIA: AI momentum and bookings support raised 2026 outlook |
| CNC Centene Corp. | FY2026 Q3 · Calendar Q4 2026 | +506.1% | +1.0% | Centene raises EPS outlook as Medicaid remains stable |
| HCA HCA Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.6% | -3.3% | HCA Q3: Volume growth offsets payer-mix and Medicaid pressure |
| RGEN Repligen Corporation | FY2026 Q3 · Calendar Q4 2026 | +14.5% | -2.4% | Repligen: Record Q3, Higher Guidance, BioLife Integration |
| NVS Novartis AG | FY2026 Q3 · Calendar Q4 2026 | +9.3% | +2.0% | Novartis Q3 2026: Growth, Margin Expansion and Higher Guidance |
Latest beats and misses
Who reports nextBeat on EPS
- HLTFY2026 Q3 · October 27, 2026+3.4% EPS-2.1% move
- SPGIFY2026 Q3 · October 27, 2026+3.4% EPS-0.4% move
- PYPLFY2026 Q3 · October 27, 2026+10.7% EPS+2.0% move
- CMSAFY2026 Q3 · October 27, 2026+6.7% EPS0.0% move
- ITWFY2026 Q3 · October 27, 2026+2.4% EPS-0.1% move
- IQVFY2026 Q3 · October 27, 2026+2.5% EPS-0.7% move
Missed on EPS
- ARCCFY2026 Q3 · October 27, 2026-3.4% EPS-0.5% move
- WSOFY2026 Q3 · October 27, 2026-8.0% EPS-1.4% move
- IVZFY2026 Q3 · October 27, 2026-2.7% EPS-0.4% move
- SHWFY2026 Q3 · October 27, 2026-1.6% EPS-2.7% move
- BAFY2026 Q3 · October 27, 2026-33.4% EPS-10.7% move
- AREFY2026 Q3 · October 26, 2026-13401.8% EPS-5.9% move
Get the AVTR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-28T14:05:15.608732+00:00
- FN2 earnings calendar · 2026-10-28T01:23:13.546025+00:00
- Polygon adjusted daily market bars · 2026-10-28T15:30:46.314404+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-28T15:30:46.311761+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-28. For educational purposes only; not investment advice.